Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Pfizer's pain drug

Pfizer has announced that the US Food and Drug Administration has approved its drug Oxecta for use in the management of acute and chronic moderate to severe pain

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its drug Oxecta (oxycodone) for use in the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

Oxecta makes use of a technology that is designed to discourage methods of drug tampering associated with abuse of opioids. Pfizer has licensed the technology from Acura, a pharma company specialising in developing product candidates to potentially deter abuse and misuse.

Opioid analgesics such as Oxecta are prescribed for patients whose condition isn't managed by other pain treatments, but can result in overdose and death if abused.

Speaking on the approval, Olivier Brandicourt, Pfizer president and general manager, Primary Care, said: "We recognise our responsibility to physicians and patients and remain committed to appropriate access to pain treatment and developing medicines to potentially address this important public health and safety issue."

Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

21st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...